Literature DB >> 35396194

Respiratory rate index utility in high-flow nasal cannula oxygen therapy in COVID-19 pneumonia; what are the perfect boundaries?

Mariano Mazza1, Domenica Di Costanzo2, Antonio M Esquinas3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35396194      PMCID: PMC8960153          DOI: 10.1016/j.resinv.2022.02.008

Source DB:  PubMed          Journal:  Respir Investig        ISSN: 2212-5345


× No keyword cloud information.
To the Editor: We have read with interest the article by Takeshita et al. [1] on the use of the respiratory rate index as a predictor of high-flow nasal cannula (HFNC) treatment efficacy in patients with coronavirus disease 2019 (COVID-19). This study confirms the complexity of the prediction of HFNC failure [2]. However, there are some issues, in our opinion, that need to be clarified. First, the authors described “that respiratory rate (RR) after HFNC treatment was significantly higher in the HFNC failure group than in the HFNC success group, whereas the RR before HFNC treatment did not significantly differ between the two groups.” In addition, this difference became statistically significant with treatment; thus, we wonder if this data may have depended on the size of the population. Second, other factors influencing the RR, and therefore its predictive value and specificity, are not considered in the analysis and discussion: i.e., any pre-existing thoraco-pulmonary alterations affecting respiratory mechanics, associated comorbidities, and the severity of the disease. Therefore, no information regarding the method used to diagnose the presence and degree of respiratory failure and exchange of gas, nor information on the pattern and extent of lung damage due to COVID-19 pneumonia was provided (radiological score - Brixia score) [3]. The degree of patients’ alertness or presence of psychomotor agitation before starting therapy with HFNC was not clarified, and whether any sort of procedural sedation was used to favor adaptation to HFNC treatment and their influence on the results. We believe that the integration of RR with these data provides information with greater predictive power in this setting of patients, who have respiratory insufficiency with a high risk of intubation. Therefore, it is more difficult to use only the respiratory rate as a specific and sensitive predictor of HFNC failure.

Conflict of Interest

The authors have no conflict of interest to declare.
  3 in total

1.  Chest X-ray versus chest computed tomography for outcome prediction in hospitalized patients with COVID-19.

Authors:  Andrea Borghesi; Salvatore Golemi; Alessandra Scrimieri; Costanza Maria Carlotta Nicosia; Angelo Zigliani; Davide Farina; Roberto Maroldi
Journal:  Radiol Med       Date:  2022-01-26       Impact factor: 3.469

2.  High-flow nasal cannula oxygen therapy in hypoxic patients with COVID-19 pneumonia: A retrospective cohort study confirming the utility of respiratory rate index.

Authors:  Yuichiro Takeshita; Jiro Terada; Yasutaka Hirasawa; Taku Kinoshita; Hiroshi Tajima; Ken Koshikawa; Toru Kinouchi; Yuri Isaka; Yu Shionoya; Yuji Tada; Kenji Tsushima
Journal:  Respir Investig       Date:  2021-10-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.